Robert Califf (Graeme Sloan/Sipa via AP Images)

Op-ed: 5 un­set­tled is­sues a Califf-run FDA will need to tack­le in 2022 and be­yond

As Rob Califf like­ly makes his re­turn as FDA com­mis­sion­er next month, his con­fir­ma­tion hear­ing yes­ter­day of­fered a peek in­to some of the larg­er ob­sta­cles he’s go­ing to face in the com­ing months and years.

The pan­dem­ic isn’t go­ing away any­time soon with Omi­cron, and some vac­cines and ther­a­peu­tics may need to be tweaked or pulled from the mar­ket en­tire­ly as they prove to be in­ef­fec­tive against the new vari­ant. The FDA, mean­while, needs to get back on even foot­ing with some longer-term di­rec­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.